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The mammary gland is an organ with a remarkable regenerative capacity that can undergo multiple cycles of
proliferation, lactation, and involution. Growing evidence suggests that these changes are driven by the coor-
dinated division and differentiation of mammary stem cell populations (MaSC). Whereas information regarding
MaSC and their role in comparative mammary gland physiology is readily available in human and mice, such
information remains scarce in most veterinary mammal species such as cows, horses, sheep, goats, pigs, and
dogs. We believe that a better knowledge on the MaSC in these species will not only help to gain more insights
into mammary gland (patho) physiology in veterinary medicine, but will also be of value for human medicine.
Therefore, this review summarizes the current knowledge on stem cell isolation and characterization in different
mammals of veterinary importance.
The Mammary Gland
The mammary gland, the structure that distinguishesmammals from all other animal species, has the unique
task of providing nutrition for the young in the form of milk
proteins and fat [1,2]. In a mammal’s life time, the mammary
gland probably undergoes more and greater changes in size,
structure, composition, and activity than any other tissue or
organ and it is considered as one of the few body organs that
undergoes repeated cycles of structural development, func-
tional differentiation, and regression. As a result, mammary
growth is a complex process involving local and systemic
factors, as well as external influences such as environment,
climate, and diet [3,4]. Furthermore, normal development of
the mammary gland is a multidimensional process that is
controlled, in part, by its own microenvironment that en-
compasses the stromal tissue and the epithelium [5–7].
The stromal compartment is generally composed of (1) a
number of different cell types and (2) the extracellular matrix
consisting of, for example, laminin, fibronectin, collagen, and
proteoglycans [5]. The best-studied stromal component is the
fat tissue pad, composed of adipocytes, in which the network
of ductal branches is embedded. There are, however, some
striking differences with regard to the architecture of the fat
pad in different animal species. For instance, the mammary
fat pad in the postnatal mouse consists primarily of adipo-
cytes irregularly interspersed in between the fine septa of
fibroblasts and connective tissue [8,9]. In contrast, there is a
much greater abundance of interlobular fibroblastic connec-
tive tissue and only a limited number of adipocytes in the
bovine and human mammary fat pad [8,10–12].
The epithelial compartment, on the other hand, forms the
ductal network of the mammary gland and there are basi-
cally two epithelial cell types in the mammary gland: luminal
and basal. The luminal epithelium forms the ducts and the
secretory alveoli, whereas the basal epithelium consists of
myoepithelial cells [13–15]. It has been suggested that all
these differentiated mammary cells, which possess different
morphologies, characteristics, and potency, are derived from
mammary gland stem cells [16–18].
Mammary Stem Cells and Their Progeny
Because there is no consensus yet on the requirements of a
mammary cell to be typed as a true mammary stem cell, and
specific definitions are lacking in literature, we propose in
this review to abbreviate mammary stem cells into mam-
mary stem cell population (MaSC), taken into account that
this abbreviation accounts for mammary stem cells as well as
mammary progenitor stem cells.
Over the last decades, evidence for the existence of MaSC
has been accumulated mainly in mice and humans. The
groups of DeOme and Daniel were the first to demonstrate
the existence of self-renewing and multipotent adult stem
cells in the mammary tissue of mice by limiting dilution
transplantation experiments [19–21]. This was confirmed by
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Kordon and Smith, who showed that an entire murine
mammary gland could be regenerated with the progeny of a
single cell following transplantation of a tissue fragment into
mammary glands cleared from their fat pad [4]. Further-
more, it was also found that single mouse MaSC, isolated
according to their expression of the cell surface markers
CD24 and CD49f (or CD29), were capable of reconstituting a
functional mammary gland upon transplantation at limiting
cell dilutions [4,22,23]. Intense research has been performed
over the years to elucidate the murine mammary epithelial
hierarchy. The generally accepted classical model describes a
common stem cell-derived progenitor cell, which commits to
either a luminal or a myoepithelial cell fate [24]. Recently,
however, a revised model has been proposed, based on ge-
netic lineage-tracing experiments and clonal analysis of the
murine mammary gland during the different development
stages [25]. This model describes the existence of different
types of long-lived stem cells and suggests that, in contrast to
other tissues where one stem cell pool gives rise to specific
differentiated cells that will populate the organ, the mam-
mary gland is maintained by two separate populations of
unipotent progenitor cells.
In humans, MaSC have also been identified, although the
knowledge on human MaSC and breast hierarchy lags be-
hind the knowledge on the murine MaSC and mammary
gland hierarchy, mainly because of the limited access to
healthy mammary gland biopsy material [26]. To overcome
this limitation, the presence of putative mammary stem cells
in human breast milk has been proposed as a noninvasive,
alternative source of MaSC. In human breast milk, a popu-
lation of nestin-positive cells has been identified [27,28], and
upon isolation and characterization, these cells were typed as
multipotent mesenchymal stem cells [29].
In striking contrast, MaSC of veterinary animals have re-
ceived little attention to date and no information is currently
available on the presence of stem/progenitor cells in the milk
of these animals.
Why Study MaSC in Veterinary Animals?
For understanding the functional role of MaSC in normal
mammary gland development, the cleared fat pad mouse
model is frequently used [24,30]. This in vivo model allows
the transplantation and growth of MaSC into their normal
anatomical site and under the influence of a normal physi-
ological environment [24,30,31]. Also, this murine mammary
gland-free fat pad transplantation system, together with
transgenic mice overexpressing oncogenes, is the animal
model of choice for human breast cancer research [32,33].
Indeed, mice have played an indispensable and pivotal role
in the study of breast cancer and this animal species will
keep on being a major research resource in comprehending
this devastating disease [34]. However, by studying (patho)
physiological mechanisms in such models, some key insights
might be lost due to the absence of variation in the mouse
model and due to important interspecies differences between
murine and human mammary tumorigenesis. Moreover,
most mammary gland tumors in mice are viral- or toxin-
induced, which is in contrast to the natural occurrence of
breast cancer in women [35].
Intriguingly, whereas both in humans and all other
mammals, the mammary gland undergoes repeated cycles of
development, function, and dedifferentiation, mammary
cancer prevalence varies greatly among these species.
Mammary cancer is common in humans and carnivores [35],
whereas cows, horses, sheep, pigs, and even the old world
primate macaques only very rarely develop mammary tu-
mors [36]. Several influences, such as genetic, hormonal, di-
etary, and geographic factors, have been proposed to account
for this difference in prevalence, but to date, no univocal
proof for this has been found [35]. Another factor that might
be involved in the susceptibility to develop mammary tu-
mors could be differences in the functional behavior and
regulation of MaSC, the driving force behind mammogen-
esis. Therefore, we believe it is of eminent importance to
study the MaSC in different species.
Different Techniques to Isolate
and Characterize MaSC
For the isolation and characterization of MaSC, several
methods have been described and are briefly outlined below.
However, because of these different techniques, it is some-
times difficult to accurately compare the nature of the MaSC
populations obtained by these different methods.
Light staining cells
This technique is often used as a method to identify
mammary stem cells in situ, although functional data con-
firming the true identity of these cells are still missing, due to
the lack of appropriate cellular markers [37,38]. When ap-
plying the key features of multipotent stem cells, namely,
division competence, mitotic quiescence, (a)symmetric mi-
tosis, and an undifferentiated cytology [39,40], two distinct
forms have been identified using electron microscopy, i.e.,
small light staining cells (SLC) and undifferentiated large
light staining cells (ULLC) [41]. In SLC, both the nucleoplasm
and cytoplasm are characteristically pale staining, and the
nuclear-to-cytoplasmic ratio is rather high. Organelles are
small and show no structural evidence of specialized func-
tion. SLC are often present in pairs, which indicates that SLC
engage in asymmetric mitosis. They are usually free of spe-
cialized membrane contacts with neighboring cells and
present a basal location. ULLC on the other hand, are two to
three times larger than SLC and show a more intermediate
position. In contrast to SLC, ULLC sometimes contact the
lumen. Although their membrane systems are more abun-
dant, they are only slightly more developed than those of
SLC. Even so, ULLC can contain small secretory granules in
their Golgi and lipid droplets in their cytoplasm [41]. In
addition to electron microscopy, histological analysis using
light microscopy is another way to identify light staining
cells. Different histological stains can be chosen, but a mix-
ture of a basic dye like toluidine blue and azure II is the most
frequently used option. On light microscopy, SLC typically
show a very sparse distribution of mitochondria and almost
no visible fibrillar mesh [38].
Functional markers
Flow cytometry analysis using the DNA-binding dye
Hoechst 33342, and to a lesser extent Rhodamine-123, is a
unique method to identify potential MaSC [42]. This method,
which depends solely on dual-wavelength flow cytometric
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analysis of cells stained with the DNA-binding dye, was
developed by Goodell and his coworkers originally as a
method to identify murine hematopoetic stem cells and was
later adapted to study stem cells in a variety of tissues, in-
cluding the mammary gland [43]. This method is based on
the fact that MaSC have the capacity to exclude this dye since
stem cells express ATP-binding cassette transporters, leading
to a Hoechst-negative population termed the side population
(SP), which is highly enriched in MaSC.
Another functional characteristic to identify potential MaSC
is their high aldehyde dehydrogenase-1 (ALDH-1) activity,
which can be detected by flow cytometry as well as immuno-
histochemistry (IHC). IHC has the advantage that it can be used
to identify MaSC in situ in slides of mammary gland tissues.
Unfortunately, ALDH-1 expression is not MaSC-specific, since
progenitor cells also express this enzyme, and therefore, ALDH-
1 should always be combined with cell surface markers to in-
crease the purity of the MaSC population [17].
A third approach to functionally identify MaSC is label-
retention studies [42]. For these studies, bromodeoxyuridine
(BrdU) is most commonly used and this synthetic analogue
of thymidine is incorporated into newly synthesized DNA of
replicating cells. MaSC are considered label-retaining cells,
which keep their DNA template strand during self-renewal
or symmetric division, while passing on the newly synthe-
sized BrdU-labeled daughter strands to their progeny during
asymmetric division.
Surface markers
A commonly used method for isolation and characteriza-
tion of (cancer) stem cells is their selection based on the
presence and/or absence of tissue-specific surface markers
(Tables 1 and 2). However, a single marker selective for
MaSC is still missing and several mammary stem cell
markers [e.g., stem cell antigen-1 (Sca-1)] are controversial in
literature. The latter may be due to different isolation pro-
tocols and culture media used in different laboratories and
for different mammal species. Moreover, it still remains
elusive whether all markers used for selection also have a
functional role in MaSC biology.
Mammospheres, self-renewal
and differentiation tests
Mammospheres are nonadherent spheres, which are en-
riched in MaSC [44]. This is based on the notice that normal
epithelial cells are anchorage dependent and undergo apo-
ptosis, named anoikis, when they are cultured under cir-
cumstances they cannot attach to a substratum. This culture
technique is frequently applied to enrich for MaSC from
freshly isolated mammary gland tissues or cell lines in dif-
ferent mammal species (Fig. 1). Testing the two main prop-
erties of MaSC, namely, self-renewal and differentiation, is a
frequently used technique to characterize these cells [44]. The
sphere formation efficiency of serially cultivated cells can be
used as a self-renewal test. To this end, a limited number of
cells is seeded at a clonal density and cultivated for 7 days,
after which the number of colony-forming units (CFU) is
evaluated [45]. For the differentiation test, cells are cultured
under differentiation conditions and immunostained with
lineage-specific markers. The most common markers to
identify luminal epithelial cells are CK8, CK18, CK19, ESA,
and MUC-1; whereas CK5, CK14, smooth muscle actin, and
vimentin are the most frequently used markers to detect
basal myoepithelial cells [18,46–48].
Table 1. Overview of the Most Commonly Used Cell Surface Markers to Immunophenotype
Mammary Gland Stem/Progenitor Cells
Mammalian species
Marker Function/expression Humana Mouse/rata Cow Dog Horse
CD10/CALLA Membrane-bound protein, highly expressed on
myoepithelial and basal cells
+ - or +
CD24 P-selectin ligand, expressed on luminal cells + Medium +
CD29 Beta1 integrin, highly expressed on basal cells + High + + b +
CD31 Endothelial cell marker - - -
CD44 Involved in cell–cell interactions, adhesion, and
migration. Highly expressed on basal cells
High + + b + +
CD45 Regulates cell growth, differentiation, and oncogenic
transformation
- - -
CD49f Alpha6 integrin with low expression on luminal
cells and high expression on basal cells
High High + + b +
CD61 Beta 3 integrin + +
EpCAM
(ESA/CD326)
Epithelial-specific antigen with high expression on
luminal cells and low expression on basal cells
Low or + + NC
MUC1 (EMA) Epithelial membrane antigen with high expression
on luminal cells
- or + - or + NC
Sca-1 Stem cell antigen-1 - or + Low or + -
Ter119 (Ly76) Associates with murine glycophorin A - -
ER Estrogen receptor - - - or +
PR Progesterone receptor - -
aBased on following reviews: [17,30,42,44,81].
bUnpublished data from the authors.
NC, no cross-reacting antibodies available.
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Bovine MaSC
Several research laboratories are focused on the study of
bovine MaSC because these cells are considered interesting
targets for manipulation to manage cell growth and tissue
regeneration, thereby improving dairy cow productivity and
udder health [49]. Moreover, the bovine mammary gland
may also provide an alternative model for biomedical re-
search aimed at evaluating the role of mammary stem cells in
mammary gland function and carcinogenesis [50,51]. For the
latter, it is intriguing to note that cows do not suffer from
mammary cancer [3] and as such, studying the regulation
and functioning of bovine MaSC could identify protective
factors against mammary tumor development.
The first report of a highly proliferative cell population in
the bovine mammary gland came from Ellis and Capuco
[38]. They identified, using histological analysis of mammary
gland samples from cows, which were injected with BrdU
before euthanasia, a lightly stained parenchymal cell popu-
lation, which was proposed to function as putative MaSC.
This was based on the observation that these light cells
comprised only 10% of the parenchymal cell population, but
accounted for nearly 50% of the proliferation [38]. One year
later, the group of Holland et al. isolated a cell population
with stem cell characteristics from monolayers of bovine
mammary gland cells [52]. In line with what Ellis and
Capuco found, Holland et al. observed ultrastructurally a
population of small light undifferentiated cells that was de-
ficient in functional gap junctions, a characteristic of stem
cells. Moreover, these cells immunohistochemically ex-
pressed casein, but not connexin 43, a gap junction protein
[52]. This group named these cells bovine mammary gland
progenitor cells or BMGPC [14,53]. A couple of years later,
Capuco identified putative bovine MaSC by their retention
of labeled DNA strands and characterized these cells more
thoroughly based on the expression of the nuclear prolifer-
ation antigen Ki67 and estrogen receptor (ER)/progesterone
receptor (PR) expression [51]. Because the label retaining
Ki67-positive cell population contained ER-positive as well
as ER-negative cells, he suggested that the ER-negative cells
represent the stem cells and the ER-positive cells their pro-
genitors [51]. An in vivo study by the same group, in which
xanthosine was injected into the mammary gland of female
calves, was initiated to evaluate whether this product could
enhance the MaSC population. This was based on the fact
that xanthosine suppresses the function of p53, a protein that
promotes asymmetric cell division (resulting in a stem cell
and a progenitor cell of committed cell lineage) [49]. Their
salient findings were that xanthosine treatment resulted in a
temporary increase of label retaining mammary epithelial
cells from 0.4% in the control gland to 0.8% in xanthosine-
treated glands [49]. This finding was more recently also
FIG. 1. Representative pictures of
mammospheres from bovine (A),
canine (B), and equine (C) mam-
mary gland tissues.
Table 2. Overview of the Most Commonly Used Cell Surface Markers
Used to Immunophenotype Mammary Gland Cancer Stem Cells
Mammalian species
Marker Function/expression Humana Mousea Dog Cat
CD10/CALLA Membrane-bound protein, highly expressed on
myoepithelial and basal cells
- - -
CD24 P-selectin ligand, expressed on luminal cells - or low - or + -
CD29 Beta1 integrin, highly expressed on basal cells High High - or +
CD34 Cell–cell adhesion factor High +
CD44 Involved in cell–cell interactions, adhesion, and
migration. Highly expressed on basal cells
+ + - or + +
CD49f Alpha6 integrin with low expression on luminal
cells and high expression on basal cells
+ or - +
CD61 Beta 3 integrin + +
CD133 (prominin 1) Unknown function + + +
EpCAM (ESA/CD326) Epithelial-specific antigen with high expression
on luminal cells and low expression on basal cells
+
MUC1 (ESA) Tumor antigen +
PROCR Basal breast epithelial marker + +
ER-alpha Estrogen receptor alpha + +
EGFR Epidermal growth factor receptor + + +
Lineage markers CD2, CD3, CD10, CD16, CD18, CD31, CD64, CD140b - -
aBased on following reviews: [23,30,62,81].
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confirmed in vitro, using bovine mammary epithelial cell
lines [54].
Aside from the (immuno)histological and ultrastructural
studies described above, a couple of reports also describe the
actual isolation and characterization of bovine MaSC from
mammary gland tissue. Li et al. isolated, cultured, and
characterized bovine mammary epithelial cells with stem cell
characteristics based on (1) their growth in suspension
(mammosphere cultures, Fig. 1A), (2) differentiation char-
acteristics into epithelial-like, myoepithelial-like, and secre-
tory cells, and (3) their expression of beta 1-integrin and
alpha 6-integrin [16]. Martignani et al. used CFU assays to
study the clonogenic expansion capacities of bovine MaSC
and they found three distinct colonies, according to the size
and morphology [55,56]. One type of colony had a myoe-
pithelial phenotype based on a CK18-negative and CK14-
positive expression profile, whereas the two other colonies
had a luminal phenotype characterized by a CK18-positive
and CK14-negative phenotype [55]. Moreover, analysis of the
ALDH activity showed that ALDHhigh cells had luminal
features, whereas ALDHlow cells produced colonies with
myoepithelial features [56]. The group of Motyl identified
putative MaSC in a suspension of bovine mammary epithe-
lial cells using the fluorescent dye Hoechst 33342 [57]. This
bovine SP was estimated to account for *0.5% of the total
cell number present in the bovine mammary gland [57]. In
addition, they used the marker Sca-1 to phenotype bovine
MaSC using IHC and scanning cytometry of the mammary
tissue section. Hereby, it was found that Sca-1-positive cells
were located predominantly in the basal layer of the epi-
thelium and comprised around 2% of the total cell number
[57]. However, transcriptional profiling, using bovine gene
expression microarrays, revealed that these Sca-1-positive
cells had a high expression of genes linked with cells of he-
matopoietic origin, suggesting that these cells represent a
cell population of nonepithelial lineage [57]. More re-
cently, Rauner and Barash used a murine mammary stem
cell enrichment kit to obtain a pure population of bovine
epithelial cells [19]. Subsequently, the cells were divided
in 4 subpopulations based on their expression of CD24
and CD49f: CD24medCD49fpos (named putative stem cells),
CD24highCD49fneg (named putative progenitor cells),
CD24negCD49fpos (named basal cells), and CD24medCD49fneg
(named luminal cells). Those 4 populations were then further
characterized for expression of epithelial lineage markers,
stem cell markers, CFU capacity, and differences in the
ALDH activity. Based on the results, a cell hierarchy and
lineage commitment model was designed (Fig. 2).The puta-
tive stem cells were put on top of the hierarchy, based on
their basal origin, bipotent character, and their capacity to
form organized colonies at a high growth rate. The putative
progenitor cells were unipotent since they could only form
CK18-positive colonies, but had a high sphere formation
capacity and were therefore typed as luminal-restricted
progenitor cells. The basal cells were bipotent, but in contrast
to the putative stem cells, showed a low sphere formation
capacity and a medium growth rate and were therefore
typed as a mix of bipotent progenitor cells and more differ-
entiated myoepithelial cells. The last subpopulation, the lu-
minal cells formed unorganized, strong CK18-positive
colonies and had a low sphere formation capacity along with
a very slow growth rate. Based on this, these cells were
proposed as the milk producing cells with hardly any pro-
liferation and were placed at the bottom of the hierarchy
model [18].
Finally, one group attempted to confirm in vivo the exis-
tence of stem cells in the bovine mammary gland through
xenotransplantation of bovine MaSC into the cleared mouse
mammary fat pad, but this was found to be extremely chal-
lenging [58]. This is most likely due to the inherent differences
between the fat pad in mice, which mainly consist of adipo-
cytes, and the much more fibrous bovine fat pad. A possible
solution to this technical problem might be the simultaneous
addition of bovine stromal fibroblasts, in line with what has
been described for a human-in-mouse model. Hereby, func-
tionally normal human breast tissue could be reproducibly
recreated in the cleared fat pad of mice when human stromal
fibroblasts were simultaneously incorporated [59].
Canine/Feline MaSC
The interest of researchers active in the field of canine and
feline stem cell research is predominantly focused on the
cancer stem cell (CSC) theory. This theory states that in es-
sence, cancer is a true stem cell disease, based on the fact that
stem cells are the only cell type in an adult organ that persist
long enough to acquire enough mutations to transform into
malignant cancer cells [60]. CSC have been identified in
several tumoral tissues as colonies of cells (spheres) that
exhibit stem cell properties, defined by their capacity for self-
renewal, gene expression profiles, and their ability to reca-
pitulate tumors in model systems [60]. However, whether
CSC are normal tissue stem cells, which have undergone
malignant transformation or whether they are more differ-
entiated cells, which have acquired more primitive, stem cell-
like characteristics due to mutations or dedifferentiation, is
not fully elucidated yet [61].
FIG. 2. Schematic illustration of the proposed hierarchy of
mammary epithelial cells in the bovine mammary gland,
based on Rauner and Barash [18] and others.
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In women, breast cancer has a high incidence and the
existence of CSC or tumor-initiating cells in breast cancer
tissues has been well documented over the years [62]. In the
female dog, mammary cancer is the most common cancer
and in female cats the third most prevalent cancer [63,64].
Also, mammary gland tumors in these companion animals
share many features with human breast cancer, including
histological appearance, biological behavior, and genetics
and therefore, these species are proposed as very valuable
animal models to study breast cancer [65,66]. However, in-
formation regarding MaSC and CSC in dogs and cats re-
mains scarce.
Cocola et al. were the first to report the isolation of normal
MaSC and CSC from dog mammary gland tissues [67]. These
cells were propagated as mammospheres and tumor spheres
for three to five passages in nonadherent cultures. Moreover,
these cells displayed self-renewing properties, multilineage
differentiation potential, could form tubular structures in
vitro and tumors in vivo in NOD/SCID mice. Marker ex-
pression analysis using western blot showed that canine CSC
were clearly positive for CD49f, CD133, p21, and CK14 and
moderately positive for CD29 and CD44 [67] (Table 2). Un-
fortunately, no data on the expression of these markers in
normal MaSC was given, so it remains to be determined
what the expression pattern is on normal MaSC and whether
there is a difference between normal MaSC and CSC. Pre-
liminary data from our research group, however, showed
that canine MaSC isolated from healthy mammary gland
tissue and grown in mammospheres (Fig. 1B) were positive
for CD29, CD44, CD49f, and the proliferation marker Ki67
(unpublished data, Table 1). CD44 is a highly conserved
transmembrane glycoprotein, which is used as a marker to
identify human CSC in primary tumors, including breast
cancer and cancer cell lines of diverse origin [68–70]. Re-
cently, it was investigated whether CD44 could also prove a
valuable marker to identify canine CSC [71]. Hereby, it was
found that, using the canine adenocarcinoma cell line
REM134, CD44high cells proliferated more rapidly and had a
much higher colony forming and tumor sphere formation
capacity in comparison to CD44low cells. Although this ob-
servation was indicative for a CD44high CSC population, the
fluctuation in expression patterns when culturing these
CD44high and CD44low populations led the authors to con-
clude that the use of CD44 as a CSC marker is limited in
canine cancer research [71]. Another research group charac-
terized spheres derived from canine mammary gland ade-
nocarcinoma cell lines using flow cytometry and RT-PCR
analyses. Their salient findings were that the sphere cell
population was predominantly CD44+CD24 - and had a
higher expression of stem cells markers, including CD133,
CD34, Notch 3, and the multidrug resistance protein, when
compared to the adherent cell population [56]. Moreover,
these CD44 +CD24 - populations showed a high ALDH ac-
tivity and were capable of initiating tumors in NOD/SCD
mice [72]. CSC spheres, isolated from REM134, were shown
to express the embryonic stem cell markers Oct4 and Nanog
as assessed by nonquantitative RT-PCR analysis [73]. The
group of Ferletta et al. [74] isolated spheres from the mam-
mary tumor cell line CMT-U229 (an atypical benign mixed
mammary tumor), characterized these spheres by IHC and
found a similar expression pattern to what had been de-
scribed by other research groups [72,73].
The first description on the isolation of feline CSC came
from the research group of Argyle, where they derived pu-
tative CSC from the feline mammary carcinoma (FMC) cell
line CAT-MT [75]. Later on, another group also characterized
CSC from FMC. These FMC-derived CSC showed in vitro
self-renewal, long-lasting proliferation and in vivo tumori-
genicity [76]. Immunofluorescence staining demonstrated
that these feline CSC were positive for CD44, ER-alpha, and
EGFR [76].
Several research groups have used the sphere assay, using
feline and canine tumors or cell lines, to evaluate the effects
of anticancer drugs. For example, the effect of recombinant
feline interferon-omega, alone or in combination with an-
thracycline chemotherapeutic drugs, was evaluated using
CSC derived from the carcinoma cell lines REM134 and
CAT-MT. Hereby, it was found that the CSC were more
resistant to the actions of interferon-omega than the
REM134 and CAT-MT cell lines [75]. A similar result was
found with the chemotherapeutic drug doxorubicin, where
spheres derived from the canine adenocarcinoma cell line
CHMp and REM134 had chemoresistant characteristics
[72,73]. Taken together, it can be stated that such sphere
assays are suitable models to test therapeutic strategies
aimed at eradicating CSC.
Equine MaSC
To date, there is only one report on MaSC in horses [45]. In
this study, MaSC were isolated from healthy mammary
gland tissue and grown as mammospheres (Fig. 1C). These
cells were immunophenotyped as CD29, CD44, CD49f, and
casein kinase 2beta-positive (Table 1) and they were able to
differentiate into luminal epithelial and myoepithelial cells
during culture in a selective differentiation medium. More-
over, the authors assessed their clonogenic expansion capa-
cities using CFU assays and studied equine MaSC in more
detail during lactation. Hereby, it was observed that equine
lactating mammary glands contained significantly more
mammosphere-initiating cells than the inactive, nonlactating
gland (a reflection of MaSC self-renewal) and moreover, that
these spheres were significantly larger in size upon initial
cultivation (a reflection of progenitor cell proliferation) [45].
MaSC in Other Veterinary Animals
No information is available to date on MaSC in other
animal species such as pigs, rabbits, or marine mammals,
with the exception of a few articles on small ruminants. One
group described the expression of the putative stem cell
marker Musaschi 1 (Msi 1) in the mammary glands of ewes
[77,78]. Msi 1 is an RNA binding protein associated with self-
renewal of neural, intestinal, and mammary progenitor cells
[79]. They found that Msi 1 was expressed in epithelial cells,
using IHC, and showed a strong correlation with the pro-
liferation marker Ki-67 [77]. Moreover, they found that the
expression of Msi 1 was upregulated during mammary
gland differentiation and downregulated during lactation
[78]. The actual isolation and characterization of MaSC in
sheep, however, has not been described so far. In a very
recent article, in vitro and in vivo functional assays were
used to identify the presence of MaSC in the mammary
gland of caprines [80]. Single-cell suspensions were made
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from lactating mammary tissue of goats and in vitro CFU
indicated the appearance of three morphologically distinct
colony types, which arose with frequencies of 1%–8% of the
total cells seeded. In addition, transplantation of these cells
under the kidney capsule of NOD/SCID mice resulted in the
formation of organized, bilayered epithelial structures that
were positive for CK14 and CK18 [80].
Hurdles in (Veterinary) MaSC Research
and Future Prospects
Despite extensive research, markers that allow for a clear
and consistent identification of MaSC have not been identi-
fied yet. Although several research groups, working on hu-
man and murine MaSC, have reached an agreement on the
cell surface expression profiles of mammary stem and pro-
genitor populations, only a handful of potential stem cell
markers are currently being used to search for MaSC popu-
lations in the mammary gland of mammals of veterinary
importance (Tables 1 and 2). This can partially be explained
by the limited availability of species-specific antibodies and
the lack of cross-reacting antibodies. Hereby, detection of
gene expression on the mRNA level could be a valuable al-
ternative. Unfortunately, this technique cannot be used to
isolate defined cell populations through sorting, so evaluat-
ing several antibody clones in search for cross reactivity will
remain required. Moreover, markers used in mice and hu-
mans to identify specific stem cell populations are not always
valid in other mammal species. For example, CD44 expres-
sion has been linked to mammary gland CSC in humans, but
this marker was recently shown to be inadequate as a canine
mammary gland CSC marker, due to a transient and fluc-
tuating expression [71]. Also, it needs to be kept in mind that
flow cytometry data on marker expression can be influenced
by the different fluorochromes conjugated to the antibodies,
antibody titrations, and the use of proper negative and
positive controls. All this makes it sometimes difficult to
interpret and compare data on the immunophenotypic pro-
files of MaSC between different research groups, as well as
between different mammal species. Lastly, whereas in mu-
rine, and to a lesser extent human, MaSC research, the hi-
erarchy of stem and progenitor cells in relation to marker
expression has been well defined, the actual hierarchy re-
mains to be determined in the mammary gland of other
mammals.
Another major hurdle in MaSC research is the lack of
consistency in nomenclature. Mammary epithelial stem cells,
mammary gland progenitor cells, mammary stem/progeni-
tor cells, potential stem cells, stem-like cells, mammary re-
populating units, and others, are being used to define cells in
the mammary gland with stem cell properties. Moreover, a
plethora of isolation and identification assays are employed
to obtain these cells, which makes it very difficult to compare
the obtained cellular populations. All this emphasizes the
need for more universal studies as well as more standardized
assays. Hereby, it is crucial to functionally validate each
marker and method used. So in conclusion, there is a huge
need for a consensus on the minimal requirements to isolate
and characterize MaSC in veterinary and human medicine.
Finally, in regard to breast cancer research and the po-
tential role of cancer MaSC, the spontaneous canine/feline
cancer models are still an under-used resource. However,
several research groups have isolated and characterized CSC
successfully from these species, using similar protocols de-
signed for the human/rodent model systems, indicating the
promising potential of these cells in basic as well as trans-
lational oncology research.
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